Review article: Prognosis of hepatorenal syndrome - Has it changed with current practice?

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 44-46

  Angeli, P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DOPAMINE; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ASCITES; CONFERENCE PAPER; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; SURVIVAL RATE;

EID: 4644354296     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02113.x     Document Type: Conference Paper

References (21)

1. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
2. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
3. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 out-patients. Am J Gastroenterol 1993; 88: 514-9.
4. Rodes J, Arroyo V, Bosch J. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 1975; 51: 492-7.
5. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-5.
6. Guevara M, Ginès P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma Volume expansion. Hepatology 1998; 27: 35-41.
7. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
8. Gilberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and albumin. Hepatology 1999; 30: 870-5.
9. Devoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
10. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
11. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
12. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-8.
13. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case control study. Liver Transpl 2004; 40: 140-6.
14. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunt: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25: 135-44.
15. Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-7.
16. Ginès P, Uriz J, Calahora B, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin for refractory ascites in cirrhosis. A mulicentre randomized comparative study. Gastroenterology 2002; 123: 1839-47.
17. Sanyal AJ, Genning C, Reddy KR, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634-41.
18. Brensing KA, Textor J, Perz J, et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95.
19. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
20. Mitzener SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS. results of a prospective, randomized controlled clinical trial. Liver Transpl 2000; 6: 277-86.
21. Moore KP, Wong F, Ginès P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.